Efficacy and safety of anlotinib in neoadjuvant treatment of newly diagnosed locally advanced thyroid cancer
10.3760/cma.j.cn321828-20240919-00326
- VernacularTitle:安罗替尼新辅助治疗初诊局部晚期甲状腺癌的疗效与安全性
- Author:
Jingya PAN
1
;
Liang SHI
;
Jun WANG
;
Fei YU
;
Chi HUANG
;
Tao QIAN
;
Shuhang XU
;
Feng WANG
;
Jianhua WANG
Author Information
1. 南京中医药大学附属中西医结合医院甲乳外科，南京 210028
- Publication Type:Journal Article
- Keywords:
Thyroid neoplasms;
Neoadjuvant therapy;
Protein kinase inhibitors;
Indoles;
Anlotinib
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2025;45(5):276-280
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy and safety of anlotinib neoadjuvant therapy for newly diagnosed locally advanced thyroid cancer (LATC).Methods:Twenty-four newly diagnosed LATC patients (10 males and 14 females, age (47.1±3.3) years) admitted to Affiliated Hospital of Integrated Traditional Chinese and Western Medicine of Nanjing University of Chinese Medicine were prospectively included from January 2023 to April 2024. Patients were given anlotinib neoadjuvant therapy (12mg/d, 2 weeks of medication, 1 week of discontinuation), and the efficacy of the treatment was evaluated by CT and multi-disciplinary treatment at the end of each treatment cycle. Patients assessed as suitable for surgery would be scheduled for surgery, while those who were not suitable for surgery would continue to receive neoadjuvant therapy and periodic evaluations. The primary endpoints were objective response rate (ORR) and disease control rate (DCR), and the R0/1 resection rate and adverse events (AE) after neoadjuvant therapy were observed. Paired- t test was used to analyze the differences between groups, and the Clopper-Person accurate method was used to calculate the bilateral 95% CI of ORR and other indicators. Results:Twenty-four patients received 2(2, 3) cycles of neoadjuvant therapy with anlotinib, of which 23 underwent surgery after anlotinib therapy. After neoadjuvant therapy, the mean maximum diameter of target lesions decreased by 23.5%(95% CI: 2.8%-44.3%) compared with baseline ( t=9.22, P<0.001). The ORR and DCR were 37.5%(95% CI: 18.8%-59.4%) and 100%(95% CI: 85.8%-100%), respectively. About 91.7%(95% CI: 73.0%-99.0%) of patients eventually underwent R0/1 resection. Hand and foot skin reactions, hypertension, oral mucositis, and leukopenia were common AE; grade 4 and 5 AE were not observed. Conclusion:Anlotinib can be safely used as neoadjuvant therapy for newly diagnosed LATC patients with good antitumor effects, providing better surgical opportunities for R0/1 resection.
